Dr. Freilich is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
10903 New Hampshire Ave
Food and Drug Administration
Silver Spring, MD 20993Phone+1 301-796-2044- Is this information wrong?
Education & Training
Children's National Medical Center/George Washington UniversityFellowship, Child Neurology, 2007- Children's National Medical Center/George Washington UniversityResidency, Child Neurology, 2007 - 2010
- Children's National Medical CenterResidency, Pediatrics, 2005 - 2007
Rutgers New Jersey Medical SchoolClass of 2005
Certifications & Licensure
VA State Medical License 2010 - 2026
CA State Medical License 2010 - 2020
DC State Medical License 2007 - 2016- American Board of Psychiatry and Neurology Neurology with Special Qualification in Child Neurology
Awards, Honors, & Recognition
- Super Doctors' Rising Stars 2013
- Northern Virginia's Top Doctors 2012-2014
Publications & Presentations
PubMed
- 24 citationsTemporal lobe epilepsy and focal cortical dysplasia in children: A tip to find the abnormality.Luca Bartolini, Matthew T. Whitehead, Cheng-Ying Ho, Leigh N. Sepeta, Chima O. Oluigbo, Kathryn Havens, Emily R. Freilich, John M. Schreiber, William D. Gaillard> ;Epilepsia. 2017 Jan 1
- 15 citationsPediatric status epilepticus: identification and evaluation.Emily R. Freilich, John M. Schreiber, Tesfaye Zelleke, William D. Gaillard> ;Current Opinion in Pediatrics. 2014 Dec 1
- 48 citationsNovel SCN1A mutation in a proband with malignant migrating partial seizures of infancyEmily R. Freilich, Julie M. Jones, William D. Gaillard, Joan A. Conry, Tammy Tsuchida, Christine Reyes, Sulayman D. Dib-Hajj, Stephen G. Waxman, Miriam H. Meisler, Phi...> ;Archives of Neurology. 2011 May 9
- Join now to see all
Press Mentions
- ALS Drug Gets FDA Panel Nod After Rare Second ReviewSeptember 8th, 2022
- New A.L.S. Treatment Lacks Evidence of Benefit, F.D.A. Panel FindsMarch 30th, 2022
- FDA Approves Oral Duvyzat for Duchenne Muscular DystrophyMarch 27th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
